{"url_path":"/sec/bblgw/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1419554/0001493152-26-023163-index.html","accession_number":"0001493152-26-023163","cik":"0001419554","ticker":"BBLG","issuer_name":"Bone Biologics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1419554/0001493152-26-023163-index.html","primary_entity_key":"0001419554","primary_entity_name":"Bone Biologics Corp"},"word_count":81,"has_tables":true,"body_markdown":"**Item\n1. Legal Proceedings.**\n\n \n\nIn\nthe normal course of our business, we may periodically become subject to various lawsuits. We are not presently a party to any legal\nproceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business,\nresults of operations, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because\nof defense and settlement costs, diversion of management resources and other factors."}